Increases in functional glial activation with age might explain why there is a decreased APOE4-associated risk for AD from of 70–80 years, and why progression to dementia in carriers of both APOE4 and BCHE-K is at least 2-fold greater below 75 years of age compared to older carriers [33]. This evidence concerns the gene APOE and Alzheimer disease.